Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
A.C. Ignatowski.
Influence of animal food on the organism of rabbits.
Izv Imp Voyenno-Med Akad Peter, 16 (1908), pp. 154-173
[2.]
M.M. Moghadasian, J.J. Frohlich, B.M. McManus.
Advances in experimental dyslipidemia and atherosclerosis.
Labor Invest, 81 (2001), pp. 1173-1183
[3.]
A. Marzal-Casacuberta, J.C. Escolà-Gil, J. Julvé-Gil, F. González-Sastre, F. Blanco-Vaca.
Modificación genética de animales de laboratorio (I): metabolismo lipoproteico y arteriosclerosis.
Clin Invest Arterioscl, 10 (1998), pp. 31-43
[4.]
A. Marzal-Casacuberta, J.C. Escolà-Gil, J. Julvé-Gil, F. González-Sastre, F. Blanco-Vaca.
Modificación genética de animales de laboratorio (II): metabolismo lipoproteico y arteriosclerosis.
Clin Invest Arteriosc, 10 (1998), pp. 34-43
[5.]
M.H. Moghadasian.
Experimental atherosclerosis. A historical overview.
Life Sci, 70 (2002), pp. 855-865
[6.]
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S).
Lancet, 344 (1994), pp. 1383-1389
[7.]
Prevention of cardiovascular events and death with paravastatin in ischeamic disease (LIPID) study group.
N Engl J Med, 335 (1996), pp. 1001-1009
[8.]
F.M. Sacks, M.A. Pfeffer, L.A. Moye, J.L. Rouleau, J.D. Rutherford, T.G. Cole, et al.
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Eventts Trial investigators.
N Engl J Med, 335 (1996), pp. 1001-1009
[9.]
J. Sheferd, S.M. Cobbe, I. Ford, C.G. Isles, A.R. Lorimer, P.W. McFarlane, et al.
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronay Prevention Study Group.
N Engl J Med, 333 (1995), pp. 1301-1307
[10.]
J.R. Downs, M. Clearfield, S. Weis, E. Whitney, D.R. Shafiro, P.A. Beere, et al.
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention study.
JAMA, 279 (1998), pp. 1615-1622
[11.]
J.C. Verd, C. Peris, M. Alegret, C. Díaz, G. Hernández, M. Vázquez, et al.
Different effect of simvastatin and atorvastatin on key enzymes involved in VLDL synthesis and catabolism in high fat/cholesterol fed rabbits.
Br J Pharmacol, 127 (1999), pp. 1479-1485
[12.]
B.R. Krause, R.S. Newton.
Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models.
Atherosclerosis, 117 (1995), pp. 237-244
[13.]
N. Roglans, E. Sanguino, C. Peris, M. Alegret, M. Vázquez, T. Adzet, et al.
Atorvastatin treatment induced PPAR alpha expression and decreased plasma non-esterified fatty acids and liver triglyceride in fructose fed rats.
J Pharmacol Exp Ther, 302 (2002), pp. 232-239
[14.]
T.M. Bocan, M.J. Mazur, S.B. Mueller, E.Q. Brown, D.R. Sliskovic, P.M. O’Brien, et al.
Antiatherosclerotic activity of inhibitors of 3- hydroxy-3-methylglutarylcoenzymeA reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation.
Atherosclerosis, 111 (1994), pp. 127-142
[15.]
S.C. Busto, M.A. Hernández-Presa, M. Ortego, J. Tunon, L. Ortega, F. Pérez, et al.
HMG-CoA eductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis.
J Am Coll cardiol, 32 (1998), pp. 2057-2064
[16.]
J.V. Ortega, B. García-Pérez, J. Fernández Pardo, M.T. Castells, S. Escobar, M. Valdés.
Efecto antiaterogénico de la atorvastatina en pollos alimentados con una dieta rica en colesterol.
Clin Invest Arterioscl, 14 (2002), pp. 225-229
[17.]
M. Takemoto, J.K. Liao.
Pleiotropic effects of 3-hydroxy-3-methylglutarylcoenzymeA reductase inhibitors.
Arterioscl Thromb Vasc Biol, 21 (2001), pp. 1712-1719
[18.]
B.G. Brown, L. Hillger, X.Q. Zhao, D. Poulin, J.J. Albers.
Types of change in coronary stenosis severity and their relative importance in overall progression and regression of coronary disease: observations from the FATS Trial: Familial Atherosclerosis Treatment Study.
Ann NY Acad Sci, 748 (1995), pp. 407-418
Copyright © 2002. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.